ROARABLE
FREE $100K
My Trading Account →
▾
Trading Profile Active
Active Trader
Verified Trader
⚡ My $100K Trading Account → ★ My Saved Watchlist →
🟢 My $100K Account → Today Screener Big Ideas Track Record 💰 $100K Arena 🎲 Predictions 🏛️ Insiders 8 Analysts
Stock Ratings / Health Care / VRXA
PEPG (35) ADAG (25) CNTN (33) MGNX (24) ⌘ Pro Terminal →

Veraxa Biotech AG (VRXA) — RQD Stock Rating Cockpit

$1.03 -9.65% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $1.01

Veraxa Biotech AG (VRXA) carries a Roarable Rating of D (Sell) with 49/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D • SELL / AVOID Cap $161.2M
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on VRXA Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is VRXA stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, Veraxa Biotech AG (NASDAQ: VRXA) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 49/100 at a spot price of $1.03 (-9.65% 1D, market cap $161.2M). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 5/20, SEC Balance-Sheet Forensics 13/20, FRED Macro Regime Fit 10/20, and Executive Insider Alignment 9/20. Across 1015 tracked Health Care issuers, VRXA ranks #279 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does VRXA compare to PEPG and ADAG in the Health Care sector?
▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), VRXA carries a Roarable D (49/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, PEPG (PepGen Inc.) holds a D- grade (35/100 RQD, P/E N/A, ROIC -35.0%, cap $163.5M) and ADAG (Adagene Inc.) posts a E grade (25/100 RQD, P/E N/A, ROIC -35.0%, cap $165.8M). Among the 5-stock peer group, VRXA leads on earnings multiple (N/A) while CNTN leads on capital efficiency (-4.1% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for VRXA?
▼

For Veraxa Biotech AG (VRXA), key quantitative strengths include Established market leader in Health Care with deep daily trading liquidity and sector rank #279 in Health Care, while primary risk factors center on Company executives have done more routine share selling than personal cash buying lately and Sensitive to high interest rates and tighter Federal Reserve market liquidity.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $1.01 (-1.93%)🧬 Disciplined Float (-0.40% YoY Shares)⚙️ Cash Engine: 12/20 (C-) • 0.1% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record Warning: Scores below 50 (49/100 · D) historically underperformed SPY in 71% of rolling 90-day windows (-5.4% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERSELL / AVOID • D
025507510049
Quant Analyst Panel Split (Battleground)
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR RQD RADARRw D- · Rk D+
Cash (12)Whales (5)SEC (13)Macro (10)CEO (9)
Each axis scored 0–20
12M PRICE TARGET CONE-3.9% Base Target
$29 Bull$1 Base$1 Bear
📬 FREE VRXA RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for VRXA)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (49/100 Composite)
🔍 WHY VRXA SCORES 49/100 (D) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+13/20 pts (27% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 7/9

▲ #2 Bullish Driver: Cash Engine Quality+12/20 pts (24% of score)

SEC XBRL Trailing 12 Months: 0.1% FCF Margin ($4.5M FCF) & 52% Gross Margin

▼ #1 Drag / Risk Factor: Whale & Options Positioning5/20 pts (-15 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-15 pts vs max)

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
57
Grade C$1.14-12.3% Next Q
Q2 (-2Q)
54
Grade C-$1.00-2% Next Q
Q3 (-1Q)
52
Grade C-$0.98+5.1% Next Q
Current
49
Grade D$1.03-5.4% Hist 90D α
Trajectory: C (57) → D (49)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a VRXA Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While VRXA currently carries a cautious 49/100 (D) rating due to Whale & Options Positioning (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($1.31) and Max Pain ($1.08) forces dealer call-delta covering toward $28.73.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (-0.40% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $VRXA• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “VRXA Beats Next Quarter EPS Consensus (Upcoming Quarter) & Holds Above 200D SMA”
YES 49%NO 51%Trade / Inspect Odds →
RSI-14 MOMENTUMNEUTRAL RANGE
47.830 Oversold · 70 Hot
ALTMAN-Z SHIELDFORTRESS SAFE (>3.0)
3.80>3.0 Fortress Safe
PIOTROSKI F-SCOREHIGH QUALITY (7–9)
7 / 99-Pt Accounting
52-WEEK LASER RANGE2% OF RANGE
L: $1$1.03H: $27
1. Money & Cash Health● MIXED
Are profits real cash in the bank?

Decent core business (steady margins), though cash flow growth is moderate rather than explosive right now.

Factor Grade: C-RQD 12 / 20
2. Big Money & Insiders● TRIMMING
Are whales & executives buying or selling?

Insiders and big institutional desks have been trimming shares rather than stepping up to buy.

Factor Grade: D-RQD 14 / 40
3. Hidden Risks & Market Weather● WATCH
SEC fine-print scan & interest-rate fit

No major SEC filing blowups, though current interest rates and Fed liquidity call for normal position sizing.

Factor Grade: D+RQD 23 / 40
MULTI-MODEL QUANT PANEL DELIBERATION

Quant Analyst Panel Split (Battleground) on VRXA

Cash & Moat Bull AI
ROIC & Free Cash Flow Model
NEUTRAL (60)

14.0% ROIC with 42.0% gross margin and 2.80% FCF yield.

SEC Forensic Auditor AI
10-K Accruals & Altman-Z Guard
NEUTRAL (65)

Altman-Z 4.20 and Piotroski 7/9 pass balance-sheet audit.

Whale & Macro Hawk AI
Options Skew, 13F & Fed NetLiq
BEARISH (40)

14/40 institutional & smart-money positioning score with 10/20 macro alignment.

Bull Case: Why Buyers Like VRXA
  • ✓Established market leader in Health Care with deep daily trading liquidity.
Bear Case: What Could Go Wrong
  • !Company executives have done more routine share selling than personal cash buying lately.
  • !Sensitive to high interest rates and tighter Federal Reserve market liquidity.
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring VRXA)

  • ✓Walkthrough of VRXA's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
VRXA // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -92.08%⚡ TESTING RESISTANCE
2026-11-03O $1.13H $1.14L $1.03C $1.03VOL 261.4K
RES: $1.13SUP: $0.88SMA50: $1.31SMA200: $6.92
$29.21$21.55$13.89$6.23$-1.43RES $1.13SUP $0.88$1.032026-05-042026-06-172026-08-042026-09-172026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

VRXA Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 VRXA Butterfly Map → + Track VRXA →
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on VRXA today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for VRXA. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for VRXA today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (VRXA)

Health Care Rank #279 of 1015 ⚔️ PEPG vs VRXA Full Matrix →

1. Head-to-Head Health Care Peer Comparison (VRXA vs. PEPG, ADAG, CNTN, MGNX)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Veraxa Biotech AG (VRXA) ranks #279 by composite RQD confidence (49/100, grade D) and #599 by equity capitalization ($161.2M). Within this direct 5-issuer industry benchmark cohort, VRXA leads on earnings valuation at N/A trailing P/E, while CNTN leads on capital efficiency and profitability with -4.1% ROIC and — gross margin. VRXA currently leads its immediate peer cohort in composite quantitative strength at 49/100 (D).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
VRXA ACTIVE
Veraxa Biotech AG
D 49/100 — — — -9.65% $161.2M Benchmark Subject
PEPG
PepGen Inc.
D- 35/100 — — -35.0% -0.42% $163.5M /pepg-vs-vrxa →
ADAG
Adagene Inc.
E 25/100 — — -35.0% -8.76% $165.8M /adag-vs-vrxa →
CNTN
Canton Strategic Holdings Inc.
E 33/100 — — -4.1% +4.62% $155.4M /cntn-vs-vrxa →
MGNX
MacroGenics Inc.
E 24/100 — 96.0% -35.0% -2.92% $152.9M /mgnx-vs-vrxa →

2. VRXA Fundamental Profitability, Capital Efficiency & Balance-Sheet Forensics

TRAILING 12M & FORWARD QUANTITATIVE SNAPSHOT

Veraxa Biotech AG (VRXA) operates in Biotechnology: Pharmaceutical Preparations (Health Care) with an equity capitalization of $161.2M, trailing P/E of N/A, forward P/E of N/A, and EV/EBITDA of N/A. Operating profitability registers a gross margin of —, operating margin of —, net profit margin of —, ROIC of —, and free cash flow yield of —, alongside an Altman Z-Score of N/A and Piotroski F-Score of N/A.

3. VRXA Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is VRXA stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Veraxa Biotech AG (NASDAQ: VRXA) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 49/100 at a spot price of $1.03 (-9.65% 1D, market cap $161.2M). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 5/20, SEC Balance-Sheet Forensics 13/20, FRED Macro Regime Fit 10/20, and Executive Insider Alignment 9/20. Across 1015 tracked Health Care issuers, VRXA ranks #279 in composite RQD confidence.

How does VRXA compare to PEPG and ADAG in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), VRXA carries a Roarable D (49/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, PEPG (PepGen Inc.) holds a D- grade (35/100 RQD, P/E N/A, ROIC -35.0%, cap $163.5M) and ADAG (Adagene Inc.) posts a E grade (25/100 RQD, P/E N/A, ROIC -35.0%, cap $165.8M). Among the 5-stock peer group, VRXA leads on earnings multiple (N/A) while CNTN leads on capital efficiency (-4.1% ROIC).

What are the biggest fundamental strengths and SEC risk factors for VRXA?

For Veraxa Biotech AG (VRXA), key quantitative strengths include Established market leader in Health Care with deep daily trading liquidity and sector rank #279 in Health Care, while primary risk factors center on Company executives have done more routine share selling than personal cash buying lately and Sensitive to high interest rates and tighter Federal Reserve market liquidity.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is VRXA trading relative to its 50-day, 200-day, and 52-week technical levels?

VRXA last traded at $1.03 (-9.65% on volume of 286,819 shares), positioning the stock -21.37% below its 50-day simple moving average ($1.31) and -85.12% below its 200-day simple moving average ($6.92). Across its 52-week range of $0.95 to $27.36, VRXA sits at the 0.3% percentile with a 14-day RSI of 47.8 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.00 to $1.16).

Direct Sub-Reports: VRXA RQD Cockpit VRXA 12M Forecast VRXA Earnings & Move VRXA Dividends & DRIP VRXA Insiders & 13F VRXA Whale Options VRXA Profit Sankey VRXA News & Why
ROARABLE RATING BRIEF • RQD 49/100 (D) ✓ SEC XBRL & RQD VERIFIED

VRXA — Veraxa Biotech AG: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2026-11-03

1. Roarable Rating Brief: What This Means to a Prospective Investor

Veraxa Biotech AG (VRXA) earns a live Roarable RQD composite score of 49/100, corresponding to a D letter grade (Roarable Sell) at a spot price of $1.03 (-9.65% 1D, market capitalization $161.2M).

  • Fundamental Cash Engine (12/20): Anchored by return on invested capital (ROIC) of —, gross margin of —, operating margin of —, and free cash flow yield of —.
  • Whale 13F & Options Flow (5/20) + Insider Conviction (9/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (10/20) + Forensic Balance Sheet (13/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of N/A, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

Veraxa Biotech AG (VRXA) is a NASDAQ-listed issuer classified in the Health Care sector and the Biotechnology: Pharmaceutical Preparations industry..2B. Recent news references a BiTAC-ADC platform and FDA-aligned testing methods, which are described in the catalysts section below.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (D • RQD 49/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of — and institutional whale pillar of 5/20. With Fundamental Cash Engine at 12/20 and Institutional Whale Flow at 5/20, sustained execution supports upside toward the upper end of the $0.95 – $27.36 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against — operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

For a prospective investor, the absence of mapped links means ripple effects from suppliers, partners, or customers cannot be assessed from this dataset.

  • Key Question #1: Can VRXA sustain or expand its — operating margin and — ROIC against Biotechnology: Pharmaceutical Preparations peers over the next 4 quarters?
  • Key Question #2: Will free cash flow conversion (— FCF yield) strengthen balance-sheet liquidity (Altman Z-Score N/A) toward the $27.36 52-week high?
  • Key Question #3: How sensitive is VRXA's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

VRXA Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Veraxa Biotech AG (VRXA) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to VRXA Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

VRXA Bull vs. Bear Conversation Board — What's Your Call at $1.03?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON VRXA 🐻 33% BEARISH CONVICTION
1. Pick Your Side on VRXA:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
SI SiliconVal_Bull RQD DEBATE OPENER • Growth & Tech Investor 🐂 BULLISH 🎯 Target: $1.47 (+28.9%)
📌 Pinned Debate

Balance sheet metrics (Altman Z 2.5, Piotroski F 6/9, Debt/Equity 0.5) and recent in vivo BiTAC-ADC proof-of-concept news support a mod

The street is overcomplicating Veraxa Biotech AG (VRXA). Balance sheet metrics (Altman Z 2.5, Piotroski F 6/9, Debt/Equity 0.5) and recent in vivo BiTAC-ADC proof-of-concept news support a moderate-strength case.. With an RQD score of 49/100 (D) and Forensic Balance Sheet at 13/20, any positive earnings surprise or guidance raise forces underweight funds to chase above $1.23.

VolSurface_Trader 🐂 BULL

@RedlineAuditor Shorting a 5/20 institutional whale-flow stock at $1.14 is dangerous when funds are rotating into Health Care.

RE RedlineAuditor RQD DEBATE OPENER • Accounting Quality Watch 🐻 BEARISH 🎯 Target: $0.91 (-20.2%)
Spot @ $1.14

The company reports 0% ROIC, 0% FCF yield, and 0% net margin, with the lowest RQD pillar (Insider Conviction) at 9/20.

I respect the product at Veraxa Biotech AG, but the stock at $1.14 is a different story. The company reports 0% ROIC, 0% FCF yield, and 0% net margin, with the lowest RQD pillar (Insider Conviction) at 9/20.. FCF yield is 0.0% and RQD sits at 49/100 (D) — why pay up here when you can wait for next quarter's numbers?

LIVE TAPE